The new GMP facility, planned to open in late 2012, will provide an additional 30,000ft2 of space.
The investment marks a significant expansion of scale for the company and includes six new GMP suites, new laboratories and a clinical packaging suite, enabling the firm to manufacture highly potent compounds up to level OEB 4.
Molecular Profiles will handle a range of dosage forms including solids, liquids, semi-solids and inhaled products in the new facility, allowing it to cover Phase I and II clinical trial requirements with manufacturing batch scale of up to 30kg.
The new facility will complement the existing GMP facility and research laboratories, providing increased productivity across the company’s drug development services portfolio.
The investment will enable expansion across all services including formulation development, polymorph and salt selection, analytical services, materials characterisation and clinical trial manufacturing.
The UK government has provided a regional growth fund grant of £1.6m towards the project.
Nikin Patel, chief executive of Molecular Profiles, said: ‘The construction of significantly larger manufacturing and laboratory facilities is a strategic decision based on customer demand. Our strategy for expansion is well underway and securing the regional growth funding is a clear endorsement of our strategic growth plans.’
